Homologous recombination has been recognized in recent years to be an important DNA repair pathway in mammalian cells, for such damage as chromosomal double-strand breaks. Cells mutated for the genes involved in the hereditary breast and ovarian cancer susceptibility syndromes, i.e. BRCA1 and BRCA2, show defects in DNA repair by homologous recombination, implicating this repair pathway in protecting individuals against tumorigenesis. This review summarizes recent advances in our understanding of BRCA1 and BRCA2 in DNA repair, as well as insight into these proteins gleaned from structure determination of domains of these proteins and the broader evolutionary conservation than previously appreciated.
Introduction
Individuals that carry a germline mutation in BRCA1 or BRCA2 are predisposed to breast, ovarian, and a few other cancers Welcsh and King, 2001) . Following the paradigm of tumor suppressor genes, one mutated allele of BRCA1 or BRCA2 is inherited and then somatic mutation occurs to alter the second allele, such that tumors invariably contain two mutant alleles. The lifetime risk associated with inheritance of a mutated BRCA1 or BRCA2 allele, while significant, has nevertheless proved difficult to estimate precisely (Begg, 2002) .
BRCA1 and to a lesser extent BRCA2 have been implicated in diverse cellular processes Welcsh and King, 2001) , including recently the maintenance of X chromosome inactivation (Ganesan et al., 2002) . However, several lines of investigation strongly implicate both of these nuclear proteins in the DNA damage response. BRCA1 and BRCA2 mutant cells exhibit a high degree of spontaneous and induced chromosome aberrations (Kraakman-van der Zwet et al., 2002; Moynahan et al., 2001a; Patel et al., 1998; Shen et al., 1998; Tirkkonen et al., 1997; Turner et al., 2002; Xu et al., 1999) , are sensitive to DNA damaging agents (Bhattacharyya et al., 2000; Connor et al., 1997; Gowen et al., 1998; Kraakman-van der Zwet et al., 2002; Morimatsu et al., 1998; Moynahan et al., 2001a; Scully et al., 1999; Shen et al., 1998; Zhong et al., 1999) , including ionizing radiation and cross-linking agents, and have elevated mutation rates (Kraakmanvan der Zwet et al., 2002; Tutt et al., 2002) . During S phase or upon treatment of cells with DNA damaging agents or replication inhibitors, both proteins are in nuclear foci along with several other proteins involved in the damage response, including the DNA repair protein RAD51 (Chen et al., 1998a; Scully et al., 1997a,b) . Nuclear focus formation, at least for BRCA1, is affected by proteins involved in the damage response (Bassing et al., 2002; Celeste et al., 2002; Wang et al., 2002) . In addition, BRCA1 is phosphorylated in a cell cycle manner (Ruffner and Verma, 1997; Scully et al., 1997a) and after genotoxic stress in a manner dependent upon the DNA damage signaling proteins ATM, ATR, and CHK2 (Cortez et al., 1999; Gatei et al., 2000 Gatei et al., , 2001 ; Lee et al., 2000; Tibbetts et al., 2000) , and Brca1 or Brca2 mutation in mice leads to the induction of the p53-p21 DNA damage checkpoints (Connor et al., 1997; Hakem et al., 1996; Patel et al., 1998; Suzuki et al., 1997; Xu et al., 2001b) .
A major challenge is to determine the molecular roles of BRCA1 and BRCA2 in the cellular response to genotoxic stress. The association of these proteins in nuclear foci with RAD51, the homolog of the prokaryotic RecA protein, implicates these proteins in homologous recombination, a DNA repair pathway in which a damaged DNA molecule uses a homologous sequence to direct repair . RAD51 directly interacts with peptides derived from BRCA2 (Mizuta et al., 1997; Wong et al., 1997) . Thus far, however, a direct protein-protein interaction between BRCA1 and RAD51 has not been reported, suggesting that the association is indirect.
Because multiple genetic hits are necessary for tumorigenesis, individuals that carry germline mutations in DNA damage response genes are particularly cancer prone, due to the hypermutability of their cells (Vogelstein and Kinzler, 1998) . Thus, like other DNA repair pathways homologous recombination may guard cells from becoming tumorigenic. As yet, there is scant evidence to support this based on the analysis of widely conserved recombination genes, i.e., RAD51 itself, the RAD51 paralogs, RAD52, and RAD54 (Pierce et al., 2001) . However, the interaction of BRCA proteins with RAD51, especially the direct interaction with BRCA2, strongly suggests a connection between this DNA repair pathway and tumor suppression. This review summarizes recent developments in our understanding of the structure and biochemical activities of the BRCA proteins and then reviews evidence which implicates BRCA1 and BRCA2 in DNA repair by homologous recombination. Mouse tumor models and characteristics of the human disease are discussed in the subsequent review (Moynahan, 2002) .
BRCA1 and BRCA2 basics: sequence conservation, structure determinations, and biochemical activities Notable about the BRCA1 and BRCA2 proteins are their poor sequence conservation across mammalian species. For example, the sequence identity of human BRCA1 with mouse Brca1 is 56%, and human BRCA with mouse Brca2, 57%. This contrasts with other genomic caretaker tumor suppressor genes, such as MSH2 or XPA, where the identity between human and mouse is much higher (92% and 86%, respectively), or even with p53, where the identity is 77%. Strikingly, the RAD51 strand exchange protein, which is in nuclear foci with BRCA1 and BRCA2, is 99% identical between human and mouse. Despite the lack of strong sequence conservation, the human BRCA1 gene can rescue the embryonic lethality of Brca1 mutant mice (Chandler et al., 2001; Lane et al., 2000) , implying a functional conservation of the protein. Similarly, the human BRCA2 gene can apparently rescue DNA damage sensitivities of a hamster Brca2 mutant cell line (Kraakman-van der Zwet et al., 2002) .
Even with the overall poor sequence conservation, BRCA1 and BRCA2 are characterized by regions of higher sequence conservation. BRCA1 has two such conserved regions, a RING domain at the N-terminus and a BRCT repeat domain in the C-terminus. These two regions account for only 300 amino acids of the 1863 amino acid BRCA1 protein, however, a mere 16% of the protein. The 3418 amino acid BRCA2 has a conserved C-terminal region, but also conserved BRC motifs located in the central portion of the protein. Structural determinations have been made for several of these domains in the past year. These structures will be discussed, as well as biochemical activities that have been ascertained for these domains or other regions of the proteins.
BRCA1
Structure of the BRCA1-BARD1 heterodimeric RING domain: BRCA1 amino acids 8 -96
The BRCA1 RING domain forms a heterodimeric complex with the RING domain of BARD1, a protein originally identified through a two-hybrid screen with BRCA1 (Wu et al., 1996) . Although a large number of proteins have been found to interact with BRCA1, what is notable is that most or all of the BRCA1 in the cell appears to be in a complex with BARD1 (Yu and Baer, 2000) . Like BRCA1, BARD1 contains an Nterminal RING domain and two C-terminal BRCT domains. However, the central region of BARD1, which contains a set of ankyrin repeats not found in BRCA1, is significantly smaller than that of BRCA1, such that the protein has a total length of 777 amino acids. Perhaps because a larger fraction of BARD1 is composed of these conserved domains, its overall sequence conservation between human and mouse is greater (70%) than that of BRCA1.
The RING motif of BRCA1 was immediately recognizable when the gene was cloned (Miki et al., 1994) . RING motifs are approximately 50 amino acids and consist of 8 Cys and His residues (Cys3HisCys4) which bind two Zn2+ atoms in an interleaved fashion. The RING motifs of BRCA1 and BARD1 are each embedded within the larger RING domain of about 90 amino acids which is necessary for BRCA1-BARD1 heterodimer formation (Meza et al., 1999) . The solution structure determination clarified the role of these extra 40 amino acids (Brzovic et al., 2001b) . In each protein they form antiparallel a-helices, which interact in the heterodimer to form a four-helix bundle (Figure 1 ). The RING motifs from BRCA1 and BARD1 extend from the same side of the four-helix bundle, and although they do not pack against each other, they are in close proximity. Figure 1 Schematic representation of the BRCA1-BARD1 heterodimeric RING domain, after Brzovic et al., 2001b . The peptides of the RING domain interact at a four-helix bundle, formed by two anti-parallel a-helices from each of BRCA1 and BARD1. The RING motifs themselves, which extend from the helices, each bind two Zn2+ atoms BRCA1, BRCA2, and homologous DNA repair M Jasin
Cancer-predisposing missense mutations are found at five of the Cys residues in the BRCA1 RING motif (BIC Breast Cancer Information Core webside http: // www.nchgr.nih.gov/dir/Intramural_research/Lab_trans-fer/Bic/index.htm 1). Based on biochemical studies of the RING domain peptides, these mutations have differential effects; some completely disrupt folding of the peptide, while others, including the common C61G mutation, have a more subtle local structural effect (Brzovic et al., 2001a) . A number of unclassified variants distributed throughout the RING domain, including the dimerization helices, have been reported to the BIC database but their biochemical consequences are not known. As yet no clear evidence implicates BARD1 disruption in tumorigenesis, although a few tumor-derived mutations have been identified (Thai et al., 1998) .
Functional studies of the BRCA1-BARD1 RING domain: Ubiquitin protein ligase activity RING proteins were recognized several years ago to have ubiquitin (Ub) protein ligase activity (i.e., E3 activity), facilitating the transfer of ubiquitin from a Ub conjugating enzyme to substrate proteins. An Nterminal fragment of BRCA1 (amino acids 1 -788) was tested and found to possess such an activity, and this activity was Zn2+dependent (Lorick et al., 1999) . A truncated RING domain of BRCA1, encoding up to amino acid 78, was also found to possess Ub ligase activity, and this activity was compromised by mutation of conserved Cys residues, including C61G (Ruffner et al., 2001) .
Given that BRCA1 forms heterodimers with BARD1, Ub ligase activity for the heterodimer has also recently been examined, using N-terminal fragments of BRCA1 (amino acids 1 -342 or 1 -772) (Hashizume et al., 2001) . Heterodimeric N-terminal BRCA1-BARD1 was found to have significantly higher activity than BRCA1 or BARD1 by themselves. The tumor-derived C61G mutation again completely abolished the activity of the heterodimer. Interestingly, mutation of the cognate Cys in BARD1 (C83G) had little effect on the activity of the heterodimer (Hashizume et al., 2001) . These experiments were performed using the Ub conjugating enzyme UbcH5, which by analogy with the cCbl-UbcH7 complex, has been proposed to bind to the RING motif of BRCA1 at a region that differs from the RING motif of BARD1 (Brzovic et al., 2001b) . Thus, the BARD1 C83G mutation may not affect the interaction of the BRCA1-BARD1 heterodimer with UbcH5.
Major questions remain regarding the functional consequence of the Ub ligase activity of the BRCA1-BARD1 heterodimer and the biologically relevant substrates. The initial report of Ub ligase activity for the BRCA1-BARD1 heterodimers detected free ubiquitin polymers or ubiquitin polymers attached to another molecule, possibly a protein which could be targeted for degradation by the 26S proteasome (Hashizume et al., 2001 ). Other RING domain proteins undergo autoubiquitination, raising the possibility that the BRCA1-BARD1 heterodimer may also undergo auto-ubiquitination. This would seem to be counter to the observation that the two proteins stabilize each other Hashizume et al., 2001; Joukov et al., 2001) . Nevertheless, using an N-terminal fragment of BRCA1 (amino acids 1 to 639), the BRCA1-BARD1 heterodimer has been found to undergo auto-ubiquitination in vitro, such that both the BRCA1 fragment and BARD1 were ubiquitinated . A shorter N-terminal BRCA1 (amino acids 1 -300)-BARD1 was observed to be ubiquitinated when tested in vivo as well. Lysine 48-linked polyubiquitin chains are signals for degradation of the protein linked to ubiquitin; thus, the requirement for this amino acid in ubiquitin was tested in vitro. The N-terminal BRCA1-BARD1 heterodimer efficiently utilized ubiquitin K48R, suggesting that the ubiquitin chain signals something other than, or possibly in addition to, degradation .
Although the Ub ligase activity may be important for auto-ubiquitination, the BRCA1-BARD1 heterodimer could have other substrates as well. BRCA1 is in nuclear foci with a number of other proteins, including a phosphorylated form of the histone variant H2AX (Paull et al., 2000) . Since histone H2A and variant H2AX are known to be mono-ubiquitinated, the proteins were tested in the N-terminal BRCA1-BARD1 in vitro ubiquitination reaction and found to be ubiquitinated . Other substrates have also been proposed, including the FANCD2 protein, which undergoes mono-ubiquitination in a BRCA1-dependent manner in vivo in response to ionizing radiation (Garcia-Higuera et al., 2001) .
Heterodimerization of BRCA1 with BARD1 may have an additional consequence in addition to promoting ubiquitin ligase activity. Nuclear localization signals have been mapped to the central region of BRCA1; however, a nuclear export signal has been mapped to the RING domain of BRCA1, which opposes the action of the nuclear localization signal (Rodriguez and Henderson, 2000) . Binding to BARD1 masks the export signal, so that BRCA1 isoforms that do not contain the nuclear localization signal can still localize to the nucleus (Fabbro et al., 2002) .
In addition to BARD1, other proteins have been reported to bind the BRCA1 RING domain (Welcsh et al., 2000) , including BAP1, which interestingly is a Ub hydrolase (Jensen et al., 1998) .
Structure of the BRCA1 BRCT domain: BRCA1 amino acids 1646 -1859
Sequence analysis of BRCA1 revealed that its Cterminus contained a repeated motif of approximately 100 amino acids, which were termed BRCT repeats (BRCA1 C-terminal repeats) (Callebaut and Mornon, 1997; Koonin et al., 1996) . The recognition of this domain in BRCA1 quickly led to the identification of its widespread presence in a number of nuclear proteins involved in DNA repair. The BRCT domain and adjacent sequences have also been implicated in transcriptional activation and chromatin unfolding (Monteiro, 2000; Ye et al., 2001) .
The crystal structure of the human and rat BRCA1 BRCT domains have recently been solved, revealing similarities of the two BRCA1 BRCT repeats to each other as well as to BRCT repeats found in other proteins (Joo et al., 2002; Williams et al., 2001) . Each repeat has a central core of four parallel b strands flanked by a helices. The two repeats are arranged in a head to tail fashion with a rotation and they pack against each other at the helices and at a linker region at the interface of the two repeats.
Cancer predisposing truncating mutations are found throughout this region (BIC). A large number of missense mutations are also found, although most of these are unclassified variants. The few known cancer predisposing missense mutations in this region have been predicted to interfere with packing of the BRCT repeats to each other (Williams et al., 2001 ). Thus, when tested by assaying the sensitivity of the peptides to limited proteolysis, A1708E and, to a lesser extent, M1775R were found to destabilize the folding of the BRCT repeats (Williams et al., 2001) .
DNA binding of BRCA1
The BRCA1 RING motif was originally considered to be a potential DNA binding domain because of the similarity to Zn fingers, which are known DNA binding motifs (Lovering et al., 1993) . However, direct tests for DNA binding indicated this domain does not bind DNA (Meza et al., 1999) , consistent with this domain being involved instead in protein -protein interactions as described above. Conflicting data exists on the BRCT domain, as one report finds evidence of DNA binding by this domain (Yamane et al., 2000) , whereas a second report does not .
More recently full-length BRCA1 protein and an internal peptide (amino acids 452 -1079) have been found to bind DNA . Binding was nonspecific with regards to sequence, but preferential to branched DNA structures and long DNA molecules. Electron microscopy with the BRCA1 peptide indicates DNA loop formation, with multiple peptide molecules bound at the base of the loop. The significance of this finding is as yet unclear.
Non-mammalian BRCA1 homologs
Until recently, BRCA1 homologs had only been identified in mammalian species, including rat and dog, in addition to mouse and human. Last year chicken and frog proteins were identified as well. Chicken BRCA1 shows 33% identity overall with the human protein, although 67% identity in the RING domain (compared with 590% identity between mammalian species) and approximately 60% identity in the BRCT domains (Orelli et al., 2001) . The Xenopus laevis BRCA1 protein has a similar degree of identity with the human protein in these domains (Joukov et al., 2001 ). Xenopus BARD1 was described in the same report (Joukov et al., 2001) .
The greater divergence of the chicken sequence allowed an identification of more conserved patches of amino acids in the middle part of the protein (Orelli et al., 2001) , many of which also appear to be conserved in the Xenopus protein. These types of phylogenetic comparisons may shed light on some of the unclassified variants found in BRCA1, by hinting at which variants are most likely to alter protein function. Functional studies have not as yet been reported for the chicken protein; however, antisense experiments were performed in two-cell Xenopus embryos to determine the effect of loss of BRCA1 or BARD1 in frogs (Joukov et al., 2001) . Depletion was observed at the onset of gastrulation, with developmental abnormalities observed several hours later at the tadpole stage. Gross phenotypic abnormalities were detected, with malformations in several tissue types likely as a result of proliferation defects.
More recently, Caenorhabditis elegans BRCA1 and BARD1 orthologs have been identified, BRC-1 and BRD-1, respectively (SJ Boulton, personal communication). Phenotypic analysis of these two genes suggest a shared role in DNA repair, as with the human proteins. Interestingly, a BRCA1-related protein in Arabidopsis has also been identified, which has 24% identity in the RING domain to the human protein and 29% identity in the BRCT, although this protein has an N-terminal extension with other conserved protein motifs (Joukov et al., 2001) . It was noted that the degree of identity between the Arabidopsis protein with human BARD1 was similar to the identity with human BRCA1, perhaps reflecting a common evolutionary ancestor for BRCA1 and BARD1 which is still found in this organism. No clear fungal BRCA1 homologs have been reported; however, BRCTcontaining proteins that share features with BRCA1 have been noted, for example Crb2 in the fission yeast (Caspari et al., 2002) 
BRCA2

BRC repeats and the conserved C-terminal domain
Sequence comparison with proteins in the database did not reveal significant similarities of BRCA2 to other proteins when it was originally cloned (Tavtigian et al., 1996) . Neverthelesss, dot matrix analysis comparing BRCA2 with itself uncovered an internally repeated sequence, termed a BRC motif, found eight times within the middle third of the BRCA2 protein . A BRC repeat consensus core sequence spanning 26 amino acids has been identified by comparing multiple mammalian species, although each repeat may span a larger segment of approximately 70 amino acids (Bignell et al., 1997) . However, only five of the repeats (BRC1, 3, 4, 7, 8) conform well to the consensus. The spacing of the repeats is variable, ranging from 80 to more than 300 amino acids when considering a fixed amino acid position within the repeats, such that the entire BRC repeat region spans more than 1000 amino acids. Across vertebrate species, including chicken (Takata et al., 2002; Warren et al., 2002) , individual repeats are more similar to each other than to other repeats, and the spacing is reasonably well-maintained. In addition to the BRC repeats, two other short regions of particular conservation have been noted in this region of the protein, one between BRC1 and BRC2 and the other just downstream of BRC8 (Bignell et al., 1997; Takata et al., 2002; Warren et al., 2002) , although their significance is not as yet clear.
Although a Rad51 interacting domain was first identified at the C-terminus of the mouse Brca2 protein (Mizuta et al., 1997; , the BRC repeat region is considered to be the major RAD51 binding region of human BRCA2 (Chen et al., 1998b; Wong et al., 1997) . Six of the eight BRC repeats interact with RAD51 in yeast two-hybrid assays, although the remaining two repeats can interact with RAD51 in in vitro assays (Wong et al., 1997) . A structure determination has recently been made for an isolated BRC peptide bound to the RecA-homology domain of RAD51 (Pellegrini et al., 2002) . The BRC peptide mimics a motif in RAD51 at the monomermonomer interface of RAD51 and thus can presumably control the assembly of the RAD51 nucleoprotein filament (see below).
Following the BRC repeat region is the much more highly conserved C-terminal region, which in human and mouse share 77% identity (Mcallister et al., 1997; . Chicken BRCA2 also shares much more conservation with the mammalian proteins in the C-terminal third of the protein than it does with the middle third of the protein containing the BRC repeats or the approximately 1000 amino acid N-terminus (Takata et al., 2002; Warren et al., 2002) . The C-terminal region binds the 70 amino acid DSS1 protein, as identified by two-hybrid analysis (Marston et al., 1999) , and its structure has recently been solved in complex with DSS1 ( (Yang et al., 2002) ; see below).
The vertebrate BRCA2 homologs, especially the more distant chicken BRCA2, provide sequences for comparative analysis to attempt to assign unclassified variants of human BRCA2 (Warren et al., 2002) . Known pathogenic and polymorphic variants show a clear difference in distribution between conserved and non-conserved amino acids, suggesting that this approach may have a good predictive value to classify variants, support of which can be gained by complementary functional approaches.
Non-vertebrate BRCA2 homologs
Although BRCA2 homologs have not been identified in budding or fission yeast, BRCA2-related proteins have been identified in diverse eukaryotic species, including puffer fish, mosquito, several intracellular parasites, including trypanosome and the microspiridium Encephalitozoon cuniculi, and plants, including two in Arabidopsis and one in rice (Warren et al., 2002) , as well as more recently C. elegans (SJ Boulton, personal communication). While the C-terminal region is conserved in these BRCA2-related proteins, they have a variable number of BRC repeats. For example only four BRC repeats have been identified in the Arabidopsis protein. However, at the extremes, 15 BRC repeats have been found in the trypansome protein, although none at all in the E. cuniculi protein. Notably absent from these BRCA2-related proteins are significant N-terminal sequences upstream of the BRC repeats, so in general they are much smaller than the vertebrate proteins.
Despite the lack of identifiable homologs in both budding and fission yeast, a BRCA2 homolog was recently identified in the yeast-like fungus Ustilago maydis in a screen for DNA repair mutants (Kojic et al., 2002) . The homolog, termed BRH2, encodes a 1075 amino acid protein with only a single identified BRC repeat. The C-terminus shares more extensive similarity with the mammalian proteins, with an approximately 200 amino acid region having 38% identity with human BRCA2 in the region that interacts with DSS1.
Structure of the BRCA2 C-terminal domain with DSS1: DNA binding
The structure of the BRCA2 C-terminal domain has recently been solved bound to DSS1 (Yang et al., 2002) . Co-expression of the two proteins was found to be necessary to obtain soluble BRCA2 protein. Limited proteolysis was used to optimize the domain boundaries for crystallization, with a 736 amino acid BRCA2 peptide from mouse found to give the best diffracting crystals (approximately residues 2400 -3110). Four globular domains are present in the BRCA2 structure in a linear array, along with an unusual fifth domain extending as a tower-like structure from one of the globular domains (Figure 2) . Three of the four globular domains, each of approximately 110 amino acids, form OB folds (OB, oligonucleotide/oligosaccharide-binding), which are found in single-stranded DNA binding proteins like the mammalian RPA protein. The tower domain, which extends from the middle of the three adjacent OB folds, consists of two long a-helices capped by a three-helix bundle, the latter of which has a structure similar to DNA binding domains found in other proteins such as Hin recombinase. The other globular domain, located Nterminal to the OB folds, primarily consists of ahelices. The small protein DSS1 binds in an extended conformation to the helical domain and the first two OB folds, in part tunneling through the BRCA2 structure. DSS1 has clusters of both hydrophobic and acidic residues and binds to a portion of BRCA2 that is rich in basic, aromatic, and hydrophobic residues, leading to the speculation that in the absence of DSS1 this region of BRCA2 may have the potential to interact with single-stranded DNA (Yang et al., 2002) .
Given the structural similarity to RPA, the BRCA2 C-terminal domain, in complex with DSS1, was assayed for DNA binding (Yang et al., 2002) . Similar to other single-stranded DNA binding proteins, singlestranded DNA, either mixed sequence or oligo(dT) or oligo(dC), was found to bind to the BRCA2 peptide, but double-stranded DNA or oligo(dA) or oligo(dG), which tend to form secondary structures, did not bind. With oligonucleotides up to approximately 20 nucleotides, a single gel shift was seen; however, with longer oligonucleotides (up to 60 nucleotides), multiply-shifted species were observed. When the tower domain was deleted, only a single species was detected even with long oligonucleotides, giving rise to the speculation that long oligonucleotides, which may form secondary structures, are able to bind to the tower, perhaps at the three-helix bundle.
The structure of the BRCA2 C-terminal domain in complex with DSS1 was also solved bound to a short oligonucleotide (Yang et al., 2002) . The best crystals were obtained with the tower domain deleted. The single-stranded DNA binds in the second two OB folds (Figure 2) , in a manner similar to RPA. Of interest, three of the residues in the OB fold that makes the most extensive contact with DNA have been found to be mutated in cancers. Overall, a large number of tumor derived missense mutations in the BIC database map to the BRCA2 C-terminal domain, including four in the tower domain, which are frequently reported to be mutated. Thus, the structure of the BRCA2 Cterminal domain, together with biochemical assays such as DNA binding, provides a context in which to consider the effect of tumor-derived mutations.
Molecular analysis of homologous recombination in BRCA1 and BRCA2 mutant cell lines
The association of BRCA1 and BRCA2 with RAD51 implicated these proteins in RAD51-mediated repair of DNA damage by homologous recombination. Homologous recombination, in which an identical or similar DNA sequence directs the repair of damaged DNA in a gene conversion mechanism, can be a very precise form of DNA repair because it can restore the original sequence present before the damage occurred (Jasin, Figure 2 Schematic representation of the BRCA2 C-terminal domain in complex with DSS1 and single-stranded DNA, after Yang et al., 2002 . Two of the three OB folds, which are similar to domains found in RPA, bind single-stranded DNA in the structure determination. At the top of the Tower, the three-helix bundle (3hb), comprised of three short a-helices, may form a second DNA binding domain, possibly for double-stranded DNA. Crystallization was facilitated by co-expression of the BRCA2 C-terminal domain with the small peptide DSS1. The N-terminus of the BRCA2 peptide is at the start of the helical domain on the far right; the C-terminus is at the end of the OB3 domain on the far left 2001). Damage that is repaired by homologous recombination can arise from exogenous sources or from endogenous processes. By analogy with E. coli, homologous recombination in mammalian cells may play an important part in every cell cycle by repairing damage arising during DNA replication (Cox et al., 2000) . DNA lesions known to be recombinogenic in mammalian cells include double-strand breaks, which will stimulate homologous recombination by several orders of magnitude (Rouet et al., 1994) . Homologous repair of double-strand breaks occurs preferentially between identical sister-chromatids, with chromosome homologs or sequence repeats on heterologous chromosomes apparently used much less frequently Jasin, 2000, 2001) . Double-strand breaks can also be repaired by nonhomologous end-joining (NHEJ), a process in which DNA ends are rejoined with little or no sequence homology (van Gent et al., 2001) . Double-strand break repair has recently been examined at the molecular level in a number of BRCA1 and BRCA2 mutant cell lines, including human tumor lines and mouse embryonic stem cell lines with targeted mutations. (See Moynahan, 2002 , for a review of phenotypes of mice with targeted mutations). Both BRCA1 and BRCA2 mutant lines have been reported to have impaired homologous recombination. Some recent studies also implicate BRCA1 in NHEJ, although others have not found a role for BRCA1 in this process, as will be discussed in a separate section. In addition, evidence has been provided that BRCA2 suppresses a third double-strand break repair pathway, termed single-strand annealing, which can occur between sequence repeats.
BRCA1
The Brca1 mutant mouse embryonic stem cell line Brca1 D223-763/D223-763 has been found to have a fivefold reduction in homologous repair of a chromosomal double-strand break compared to wild type cell lines (Moynahan et al., 1999) and a severely reduced level of gene targeting (Moynahan et al., 1999 (Moynahan et al., , 2001a Snouwaert et al., 1999) . The Brca1
D223-763/D223-763
mutant is clearly a hypomorph (partial loss of function), as gauged by the longer embryonic survival of mice containing this mutation compared with null alleles (Gowen et al., 1996) and the recovery of some viable mice on a p53 background (Cressman et al., 1999) . Thus, it is possible that the fivefold reduction reflects a partial loss of function, and that complete loss of Brca1 leads to a more profound effect on homologous repair, although this has yet to be tested.
The Brca1 D223-763 mutation deletes the 5' portion of exon 11 (Gowen et al., 1996) . The hypomorphic nature of this mutation is thought to be due to the expression of a splice variant in which exon 11 is entirely skipped (Snouwaert et al., 1999) , such that exons 10 and 12 are spliced together at amino acids 222 and 1328. This splicing event maintains the reading frame of the protein, such that the RING and BRCT domain coding sequences are intact. A related mutation has also been constructed in which all of exon 11 was deleted by lox-Cre recombination (Xu et al., 1999) . This Brca1 D11 mutation also leads to expression of the exon 11-deleted splice variant, which encodes a 92 kD peptide . The participation of this peptide in the DNA damage response has been investigated. Unlike the intact 220 kD Brca1 protein, a shift in protein mobility in response to DNA damage is not detected for the 92 kD Brca1 peptide, suggesting that it is not phosphorylated . Nevertheless, like the intact protein, the 92 kD peptide localizes to nuclear foci upon DNA damage . Despite this, Rad51 localization to nuclear foci upon DNA damage is impaired ( ; see also Bhattacharyya et al. (2000)), and the 92 kD peptide does not associate with Rad51 as assayed by co-immunoprecipitation . The lack of association of the 92 kD peptide with Rad51 is consistent with previous mapping studies which concluded that Rad51 interaction was localized to a region of exon 11 (Scully et al., 1997b) , and it is also consistent with the observed recombination defect.
Proteins involved in homologous recombination in actively dividing cells are often also involved in meiotic recombination. Consistent with a role in meiosis, BRCA1 colocalizes with RAD51 during meiosis on chromosome axes prior to homolog synapsis, and in males remains associated with the unsynapsed X chromosome (Scully et al., 1997b) . A role specifically in meiotic recombination is supported by the prophase I meiotic arrest observed in Brca1 D223-763/D223-763 p53 7/7 males (Cressman et al., 1999) . Interestingly, ovaries of the one female reported in this study had growing follicles, suggesting that Brca1 may not be as stringently required for early meiotic events in female germ cells as in males (Cressman et al., 1999) . Male but not female infertility has been observed in a second line of Brca1 hypomorphic mice, in this case carrying a Brca1 truncation mutation (Ludwig et al., 2001) . The gender differences may indicate a differential role in meiotic recombination; alternatively, male-specific events involving the X-Y chromosome pair may have a particular requirement for Brca1 (see also Ganesan et al., 2002) .
BRCA2
Mouse cell lines with targeted mutations in the Brca2 gene also have been reported to have homologous recombination defects. The Brca2 lex1/lex2 embryonic stem cell line has two different alleles of Brca2: the lex1 allele in which the terminal exon 27 is deleted by gene targeting, resulting in a truncation at amino acid 3139 of the 3328 amino acid mouse Brca2 protein and the lex2 allele in which exon 27 is deleted together with a portion of exon 26 at amino acid 3088 (Morimatsu et al., 1998) . The set of BRC repeats in the central portion of the protein is therefore left intact in both alleles. The C-terminus of the protein was targeted for disruption in this study, as it was the first portion of the protein recognized to interact with Rad51 (Mizuta et al., 1997; .
When tested for repair of a chromosomal doublestrand break, a fivefold reduction in homologous repair was observed in the Brca2 lex1/lex2 cells (Moynahan et al., 2001b) . As with the Brca1 D223-763/D223-763 mutant, the Brca2 lex1/lex2 mutant is certainly a hypomorph, since, unlike mice with Brca2 null alleles, viable mice with a Brca2 exon 27 deletion can be obtained (McAllister et al., 2002) . Thus, the moderate fivefold reduction may reflect a partial loss of function, such that a Brca2 null cell line would have a more profound defect in homologous repair. Interestingly, although this fivefold reduction in homologous repair was the same as that observed in the Brca1 D223-763/D223-763 mutant, the fold-reduction in gene targeting Brca lex1/ lex2 mutant is much milder as compared with the Brca1 D223-763/D223-763 mutant (i.e., twofold vs 16-fold using the same targeting vector; (Moynahan et al., 2001a,b) ). Thus, although both proteins have a role in promoting homologous recombination, their role does not appear to be equivalent.
Nuclear localization signals in human BRCA2 have been mapped to the region of the protein that is deleted in the mouse Brca2 lex1 and Brca2 lex2 alleles (Spain et al., 1999; Yano et al., 2000) . Cell fractionation studies, however, indicated that the truncated mouse Brca2 peptide in the Brca2 lex1/lex2 cells still localizes appropriately to the nucleus (Moynahan et al., 2001b) . Consistent with this, another study has found that the N-terminus of Brca2 is sufficient for nuclear localization . The Brca2 peptide in the Brca1 lex1/lex2 cells was also found to interact with Rad51 (Moynahan et al., 2001b) , presumably through the BRC repeat region which is still intact in the truncated peptide. Thus, the Cterminus of Brca2 has a role in homologous recombination that goes beyond proper cellular localization of the protein or simply providing the interaction site for Rad51. Although a human BRCA2 mutant tumor cell line has also been found to be defective for homologous recombination (see below), it is not clear if these results with mouse Brca2 are strictly applicable in detail to human BRCA2. In addition to a dependence of the human protein on the C-terminus for nuclear localization, the human protein differs from the mouse protein in that there is no evidence that the C-terminus of human BRCA2 interacts with RAD51 (Chen et al., 1998b) .
A second Brca2 mutant mouse embryonic stem cell line has been reported to be impaired for homologous recombination (Tutt et al., 2001 ). This mutant has two different Brca2 hypomorphic alleles by gene targeting: the DEx27 allele, which like lex1 is detected for the terminal exon 27, and the Tr allele, in which Brca2 is truncated at amino acid 2014 at BRC7. Peptides from both alleles were shown to interact with Rad51 by coimmunoprecipitation, although Rad51 nuclear focus formation upon DNA damage is impaired in the Brca2
Tr/DEx27 cell line (Tutt et al., 2001) . When tested for homologous recombination, the Brca2 Tr/DEx27 cell line was found to have a 42% reduction in homologous repair of a double-strand break compared with the control Brca2
Tr/Ex27+ cell line in which the Brca2 Ex27+ allele of Brca2 is wild-type except for an epitope tag. In addition to homologous repair by gene conversion and non-homologous repair by NHEJ, another outcome of double-strand break repair is a deletion involving a sequence repeat. Such deletions can arise through annealing of single stranded DNA generated at the repeat rather that a Rad51-mediated gene conversion process (Paˆques and Haber, 1999) . Deletion events were assayed in the Brca2
Tr/DEx27 mutant and found to be about threefold elevated compared with the Brca2
Tr/Ex27+ cell line (Tutt et al., 2001) . A recent study examining spontaneously arising deletion events also found an increase in deletion events in a BRCA2 mutant (Larminat et al., 2002) . This contrasts with results from the Brca1 D223-763/D223-763 mutant, in which deletion events following a double-strand break were decreased rather than increased (Moynahan et al., 1999) . Although this could be interpreted to mean that Brca1 and Brca2 mutations have opposite effects in annealing-type repair events, this conclusion is tenuous, because Rad51-mediated repair can also give rise to deletion products at a repeat, making it difficult to tease apart the contributions of the various pathways.
Human BRCA2 has also been implicated in homologous recombination through the examination of a tumor-derived cell line. The human pancreatic adenocarcinoma cell line CAPAN-1 carries a single mutated BRCA2 allele which encodes a peptide that is truncated within BRC7 (Goggins et al., 1996) . Homologous repair of a double-strand break was examined in CAPAN-1 cells and found to be severely compromised, with an estimated approximately 100-fold reduced level compared with other cell lines (Moynahan et al., 2001b) . Gene targeting was also found to be reduced in the CAPAN-1 cells relative to cells in which wild-type BRCA2 has been re-expressed . Consistent with homologous recombination defects, DNA damage-induced RAD51 focus formation is impaired in the CAPAN-1 cell line (Yuan et al., 1999) , as in the Brca2
Tr/DEx27 cell line (Tutt et al., 2001 ) and a hamster Brca2-deficient hamster cell line (Kraakman-van der Zwet et al., 2002) . Interestingly, localization of RAD51 to the nucleus has also been shown to be altered in the CAPAN-1 (Davies et al., 2001 ) and hamster cell lines (Kraakman-van der Zwet et al., 2002) .
These studies in BRCA2 mutant mouse and human cell lines have been complemented by those using a dominant negative approach in which BRC repeat peptides are expressed in otherwise BRCA2 wild-type cell lines. The rationale for this approach is that the BRC repeat peptides will not have the full biochemical activity of intact BRCA2 but will still interact with RAD51 and compromise the interaction of functional wild-type BRCA2 with RAD51. Consistent with this, expression of a single BRC repeat fused to a heterologous protein reduces the co-immunoprecipita-tion of BRCA2 and RAD51 and results in inpaired RAD51 focus formation upon DNA damage Yuan et al., 1999) . Functional significance to these results with regards to homologous recombination assays is seen in that BRC repeat expression diminishes both BRCA2-dependent gene targeting and homologous repair of a double-strand break (Stark et al., 2002) .
BRCA2, like BRCA1, colocalizes with RAD51 during meiosis on chromosome axes prior to homolog synapsis (Chen et al., 1998a) . Thus far, however, hypomorphic mouse lines have not been informative about a role in meiotic recombination. Males from the Brca2 Tr/Tr line had an absence of germ cells in the testis, and females were devoid of obvious follicles, suggesting a loss of germ cells prior to meiosis in one or both sexes (Connor et al., 1997) . By contrast, mice in which only exon 27 was deleted were fertile for both sexes (McAllister et al., 2002) .
Ustilago maydis provides a complementary, genetically tractable system in which to examine the function of a BRCA2 ortholog in DNA repair (Kojic et al., 2002) . BRH2 was disrupted to create a null allele and then the brh2 strain was examined for recombination defects. Homologous recombination was found to be as severely reduced in the brh2 strain of Ustilago as in the rad51 mutant strain. For example, homologous repair of a plasmid double-strand break from an intact chromosome is reduced approximately 100-fold in both the brh2 and rad51 strains. Recombination between chromosome homologs is also reduced, in this case greater than 200-fold for spontaneous events and 2000-fold for UV-induced events. BRH2, like RAD51, is absolutely required for a productive meiosis in Ustilago, strongly implicating it in meiotic recombination in this organism. Similar to the observation of chromosome abnormalities in mammalian BRCA1 and BRCA2 mutants, genomic instability was elevated in the brh2 mutant, as evidenced by a 10-fold increase in loss of heterozygosity in diploids, as determined genetically, and by an increased frequency of aberrant chromosomes, as determined by pulsed field gel electrophoresis. Thus, mutation of BRH2 in Ustilago recapitulates phenotypes of mammalian BRCA2 mutants, indicating that this fungal system holds significant promise to gain further insight into cellular functions of BRCA2.
Biochemical studies of BRCA2 -an accessory factor for RAD51-mediated strand exchange?
Two recent studies have begun to examine the role of BRCA2 protein in vitro on RAD51 protein. RAD51 promotes strand exchange between homologous DNA molecules, a reaction thought to be central to homologous recombination reactions (Baumann et al., 1996) . As part of this reaction, RAD51 binds DNA to form nucleoprotein filaments. The recognition that the BRC repeats of BRCA2 bound RAD51 led to a study to determine the effect of a BRC repeat peptide on the ability of RAD51 to bind DNA (Davies et al., 2001) . When RAD51 was preincubated with an excess of BRC repeat peptide, the ability of RAD51 to bind DNA was severely compromised and nucleoprotein filament formation was disrupted. Gel filtration studies indicate that RAD51 self-associates to form a number of species, i.e., aggregates, rings, and monomers, but that the addition of a BRC repeat peptide disrupts the ability to self-associate, such that RAD51 runs as a monomer associated with the BRC repeat peptide (Davies et al., 2001) . These results are consistent with those obtained in vivo, in which expression of a single BRC repeat impairs homologous recombination (Stark et al., 2002; Xia et al., 2001) , as well as with the recent structure determination of a BRC peptide bound to RAD51 (Pellegrini et al., 2002) .
Strand exchange reactions of RAD51 involve a single-stranded DNA molecule and a homologous DNA duplex. This reaction is strongly dependent on the single-stranded binding RPA, presumably to remove secondary structure from single-stranded DNA to make it accessible for base pairing (Baumann and West, 1997) . The structural similarity of three domains of the BRCA2 C-terminal domain with the oligonucleotide binding folds of RPA led Yang et al. (2002) to determine whether the BRCA2 C-terminal domain, in complex with DSS1, could affect the requirement for RPA in RAD51-mediated strand exchange reactions. Although the BRCA2 C-terminal domain could not substitute for RPA, this domain could enhance strand exchange in the presence of RPA. Normally, this reaction has a defined order of addition, with RAD51 and DNA incubated together first and RPA added second, presumably because RPA addition first will block access of RAD51 to single-stranded DNA. Accessory factors, which have been termed mediators, have been identified which overcome this inhibition (Gasior et al., 2001) . The BRCA2 C-terminal was found to have such an activity, allowing the simultaneous addition of RPA, RAD51, and DNA for efficient strand exchange (Yang et al., 2002) .
The finding that the BRCA2 C-terminal domain stimulates RAD51 strand exchange could readily account for the impaired homologous recombination found in BRCA2 mutants. Notably, this region is not present in the truncated BRCA2 peptide in CAPAN-1 cells and in some of the mouse Brca2 truncation alleles, e.g., Brca2
Tr2014 . The C-terminal domain used in the in vitro studies is predicted to be intact, however, in other mouse alleles, i.e., Brca2 lex1 and Brca2
DEx27
. Nevertheless, the function of the C-terminal domain could possibly be perturbed by the deletion of the exon 27 sequences.
Nonhomologous end-joining (NHEJ) of double-strand breaks and BRCA1
In addition to RAD51, BRCA1 has also been found in nuclear foci with a number of other proteins involved in the DNA damage response (Wang et al., 2000) , including the RAD50 complex . Like RAD51, RAD50 is involved in homologous recombination, but unlike RAD51, RAD50 is also implicated in double-strand break repair by NHEJ (Haber, 1998; Paull, 2001) . NHEJ of DNA ends can be a precise form of DNA repair if the ends are undamaged; however, if base damage occurs or nucleotides are otherwise lost or damaged, mammalian cells can nevertheless rejoin the ends, but the rejoining is imprecise (mutagenic) in relation to the original sequence present prior to DNA damage. Thus, relative to homologous recombination, NHEJ is an imprecise mode of repair.
NHEJ has recently been examined in BRCA1 mutants by several groups, with complex results. In the mouse Brca1 D223-763/D223-763 mutant, imprecise NHEJ was examined after a double-strand break was introduced in vivo at a defined chromosomal locus (Moynahan et al., 1999) . Unlike homologous repair, the level of NHEJ was not reduced in this line, but rather was found to be slightly elevated. NHEJ was examined more recently using a similar approach in a second mouse cell line, a unique embryonic fibroblast line derived from mice carrying an apparently null allele of Brca1, as well as mutant p53 (Zhong et al., 2002b) . As with the Brca1 D223-763/D223-763 mutant, the overall level of imprecise NHEJ in these Brca1 7/7 p53 7/7 cells was not noticeably reduced relative to p53 7/7 control cells. However, a specific NHEJ product involving a 4-bp microhomology was reduced 450-fold, suggesting that Brca1 may influence a subset of NHEJ events. Although intriguing, NHEJ pathways have not been sufficiently characterized in mammalian cells to understand the significance of the loss of this particular product.
NHEJ is key to the repair of double-strand breaks generated during V(D)J recombination; thus, successful antigen receptor rearrangement in the immune system is indicative of functional NHEJ pathways. A conditional Brca1 null allele has been constructed to examine the role of Brca1 in T cell development (Mak et al., 2000) . When this allele is conditionally inactivated, exons 5 and 6 are deleted to result in a transcript encoding only the first 49 amino acids of Brca1. Although thymocyte development was arrested in a p53-dependent manner in these mice, apparently due to chromosome abnormalities, T cell receptor rearrangement was not obviously impaired, indicating that NHEJ was functional during V(D)J recombination in the absence of (Mak et al., 2000) .
Cell free extracts have also been used to examine the involvement of BRCA1 in NHEJ. In two variations of these in vitro assays, monomer length plasmid can be converted to dimers, trimers, and higher multimeric forms, mostly by precise ligation of DNA ends (Baumann and West, 1998) or, with a different cell extraction procedure, also recircularized, by either precise ligation or imprecise rejoining (Feldmann et al., 2000) . In cell extracts prepared according to Baumann and West (1998) from the Brca1 7/7 p53 7/7 mouse embryonic fibroblasts, the level of NHEJ to produce multimeric forms was reduced 3 to 10-fold relative to extracts from control cells at low Mg2+ concentrations, although the level of NHEJ at high Mg2+ concentrations was not affected (Zhong et al., 2002a) . In this study, human cell extracts immunodepleted for BRCA1 were also found to have a reduced level of NHEJ, as were extracts depleted for RAD50.
In another study, cell extracts from three BRCA1
lymphoblastoid lines from carriers prepared according to Baumann and West (1998) were examined for NHEJ (Baldeyron et al., 2002) . The extracts from the BRCA1 +/7 mutant cells were found to support less plasmid multimerization than control BRCA1 +/+ cell lines. The BRCA1 +/7 lymphoblastoid cell lines, which each carried a different BRCA1 mutation, had a lower than expected level of wild-type BRCA1 protein considering the heterozygosity of the lines, possibly accounting for the reduced NHEJ in these lines. This study also used in vivo plasmid-based rejoining assays to examine NHEJ in the BRCA1 +/7 lymphoblastoid lines (Baldeyron et al., 2002) . In this type of assay, a linearized plasmid is introduced into cells, and then the plasmid DNA is recovered and transformed into bacteria. Using this plasmid based approach, the BRCA1 +/7 lymphoblastoid lines did not show a major defect, i.e., greater than 10-fold, in the level of recircularization of the plasmid. However, the NHEJ products showed a decreased fraction of precise ligation events (i.e., on average sixfold lower), indicating a greater propensity to sequence alterations at the DNA ends prior to rejoining. The differential results obtained in the level of rejoining between the cell extract and in vivo studies may possibly reflect that the in vivo assay measures both precise and imprecise ligation events, whereas the cell extract assay primarily measures precise ligation events.
A third study has used cell free extracts prepared according to Feldmann et al. (2000) from a human BRCA1 mutant cell line that expresses no wild-type protein (i.e., HCC1937 breast carcinoma) (Me´rel et al., 2002) . Extracts from the HCC1937 cell line were found in this study to support similar levels and accuracy of NHEJ as extracts from control cell lines (Me´rel et al., 2002) . The similar level of rejoining obtained in this study is consistent with the normal in vivo NHEJ kinetics of ionizing radiation-induced double-strand breaks that have been reported for this cell line (Wang et al., 2001 ).
Thus, a few studies indicate a role for BRCA1 in certain types of NHEJ, while others do not. As each of these studies utilize different assay systems and cell lines with different mutations, it is as yet difficult to decipher whether deficiencies in particular pathways of NHEJ are a general outcome of BRCA1 mutation.
A few reports have examined the BRCA2 mutant CAPAN-1 cell line for NHEJ, using cell extracts (Me´rel et al., 2002; or rejoining of radiation-induced double-strand breaks (Wang et al., 2001) . Each of these reports reached the same conclusion, i.e., that NHEJ is not affected in this line.
Checkpoint defects and BRCA1 or BRCA2 deficiency
DNA repair deficiencies have the potential to make cells hypermutable. However, if unrepaired damage triggers a cell cycle checkpoint or apoptosis, repair deficient cells can be eliminated from the population, such that mutations cannot efficiently accumulate. Thus, a checkpoint defect may allow a repair deficient phenotype to manifest itself. BRCA1 mutant human cells and Brca2 deficient hamster cells have been shown to have a defective S phase checkpoint response to ionizing radiation (Kraakman-van der Zwet et al., 2002; Xu et al., 2001a) , suggesting that mutant cells may continue to progress through the cell cycle with unrepaired damage arising during replication. Interestingly, a separation of function mutation in BRCA1 has been identified in which the ionizing radiation-induced checkpoint has been abrogated, but cell survival after irradiation is not affected (Turner et al., 2002) . Evidence also supports a G2/M checkpoint defect Xu et al., 1999 Xu et al., , 2001a ). Thus, it is possible that DNA repair and checkpoint defects cooperate in BRCA deficient cells to produce the observed chromosome abnormalities found in these cells.
Conclusions
The association of BRCA1 and BRCA2 with RAD51 implicated these proteins in homologous recombination. Recent studies have now given strong support to this, in particular the finding of homologous recombination defects in BRCA2 mutant cell lines and a BRCA1 mutant cell line. Furthermore, biochemical and structural studies of the BRCA2 C-terminal domain place BRCA2 directly in the recombination pathway. Several challenges still remain in terms of directly linking recombination defects to tumorigenesis, particularly in a manner that explains the tissue distribution of the tumors seen in BRCA carriers, and parsing the role of the BRCA proteins in other DNA repair pathways and in checkpoint responses, especially as regards BRCA1. Certainly, the next few years promise to yield a plethora of other studies which will address these issues. Stay tuned.
